Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract seeks to advance electronic nose technologies that replicate the human olfactory system to create a reliable diagnostic platform for disease detection and monitoring, subject to validation and regulatory approval. Building on previous successes in detecting volatile organic compound (VOC) signatures from human skin, this initiative aims to enhance sensing, detection, and analytical capabilities. These VOCs serve as biomarkers for numerous diseases, and the improved technology is intended to be integrated into noninvasive diagnostic tools that complement traditional, invasive procedures like blood analysis. The goal is to enable real-time, in situ disease diagnosis and monitoring in everyday settings, facilitating earlier intervention and better disease management. This project is led by the National Center for Advancing Translational Science (NCATS), which aims to accelerate the development and delivery of treatments to a broad population. The contract specifically disallows clinical trials and is aligned with NCATS’ mission to translate scientific knowledge into practical solutions for disease prevention and treatment. Authorities for this forecasted opportunity stem from the Cures Acceleration Network under 42 U.S. Code § 287a. The program highlights the promise of using advanced biosensing technologies combined with systems engineering and artificial intelligence to revolutionize health diagnostics in a more accessible, efficient, and patient-friendly manner.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease.
NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions.
Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
